Are you Dr. Junghans?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 65 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Washington St
Boston, MA 02111Phone+1 617-636-5982
Summary
- Dr. Richard Junghans, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts and Rhode Island. He is affiliated with Good Samaritan Medical Center and Morton Hospital and Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1983 - 1986
University of Miami Leonard M. Miller School of MedicineClass of 1983
Certifications & Licensure
MA State Medical License 1991 - 2026
RI State Medical License 2004 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Start of enrollment: 1995 Jul 01
- Gene Therapy in Treating Patients With Cancer Start of enrollment: 1998 Apr 01
- Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsBenign tumors in TSC are amenable to treatment by GD3 CAR T cells in miceAncy Thomas, Saurav Sumughan, Emilia R. Dellacecca, Rohan Shivde, Nicola Lancki
JCI Insight. 2021-11-22 - 41 citationsAntigen Specificity Enhances Disease Control by Tregs in VitiligoZhussipbek Mukhatayev, Emilia R. Dellacecca, Cormac Cosgrove, Rohan Shivde, Dinesh Jaishankar
Frontiers in Immunology. 2020-12-01 - 45 citationsHITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.Steven C. Katz, Ashley E. Moody, Prajna Guha, John C. Hardaway, Ethan A. Prince
Journal for Immunotherapy of Cancer. 2020-08-01
